ArticlebioRxiv : the preprint server for biology2025

Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitors.

Vera Tiedje et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.